Mediators of Inflammation / 2013 / Article / Tab 3

Clinical Study

Human Leukocyte Antigen Class II Alleles (DQB1 and DRB1) as Predictors for Response to Interferon Therapy in HCV Genotype 4

Table 3

Frequencies and percentages of DRB1 alleles in HCV patients and healthy group and in responder and nonresponder patients to combined treatment of interferon and ribavirin.

DRB1
HCV
patients
Healthy
controls
PCResponders Nonresponders PC
( )( )( )( )

*012 (3.2%)6 (10.5%)0.2151 (2.4%)1 (4.8%)1.000
 *01021 (1.6%)9 (15.8%)0.1481 (2.4%)0 (0.0%)0.661
 *01061 (1.6%)1 (1.8%)1.0001 (2.4%)0 (0.0%)0.661
*0313 (21.0%)25 (43.9%)0.07211 (26.8%)2 (9.5%)0.187
 *03018 (12.9%)17 (29.8%)0.5526 (14.6%)2 (9.5%)0.447
 *03044 (6.5%)12 (21.1%)0.1122 (4.9%)2 (9.5%)0.417
 *03135 (8.1%)0 (0.0%)0.2223 (7.3%)2 (9.5%)0.556
 *03288 (12.9%)0 (0.0%)0.1836 (14.6%)2 (9.5%)0.447
 *03323 (4.8%)0 (0.0%)0.5561 (2.4%)2 (9.5%)0.263
*0414 (22.6%)12 (21.1%)1.00011 (26.8%)3 (14.3%)0.346
 *04033 (4.8%)13 (22.8%)0.0892 (4.9%)1 (4.8%)0.737
 *04712 (3.2%)7 (12.3%)0.1342 (4.9%)0 (0.0%)0.434
 *04454 (6.5%)9 (15.8%)0.2122 (4.9%)2 (9.5%)0.417
*0722 (35.5%)36 (63.2%)0.02915 (36.6%)7 (33.3%)1.000
 *070122 (35.5%)36 (63.2%)0.02913 (31.7%)9 (42.9%)0.277
 *070320 (32.3%)36 (63.2%)0.01313 (31.7%)7 (33.3%)0.558
 *070520 (32.3%)36 (63.2%)0.01313 (31.7%)7 (33.3%)0.558
 *07064 (6.5%)35 (61.4%)0.0002 (4.9%)2 (9.5%)0.417
 *070720 (32.3%)36 (63.2%)0.01313 (31.7%)7 (33.3%)0.558
 *07086 (9.7%)35 (61.4%)0.0003 (7.3%)3 (14.3%)0.325
 *070920 (32.3%)36 (63.2%)0.01313 (31.7%)7 (33.3%)0.558
 *0710N20 (32.3%)36 (63.2%)0.01313 (31.7%)7 (33.3%)0.558
 *071120 (32.3%)36 (63.2%)0.01313 (31.7%)7 (33.3%)0.558
 *07124 (6.5%)35 (61.4%)0.0002 (4.9%)2 (9.5%)0.417
 *07134 (6.5%)35 (61.4%)0.0002 (4.9%)2 (9.5%)0.417
 *07146 (9.7%)35 (61.4%)0.0003 (7.3%)3 (14.3%)0.325
*084 (6.5%)0 (0.0%)0.5703 (7.3%)1 (4.8%)1.000
 *08012 (3.2%)0 (0.0%)0.4341 (2.4%)1 (4.8%)0.661
 *08162 (3.2%)0 (0.0%)0.4341 (2.4%)1 (4.8%)0.566
 *08331 (1.6%)0 (0.0%)1.0001 (2.4%)0 (0.0%)0.661
*091 (1.6%)0 (0.0%)1.0001 (2.4%)0 (0.0%)1.000
 *09041 (1.6%)0 (0.0%)1.0001 (2.4%)0 (0.0%)0.661
 *09061 (1.6%)0 (0.0%)1.0001 (2.4%)0 (0.0%)0.661
*103 (4.8%)0 (0.0%)0.2823 (7.3%)0 (0.0%)0.545
 *10013 (4.8%)0 (0.0%)0.2823 (7.3%)0 (0.0%)0.282
*1112 (19.4%)7 (12.3%)0.7259 (22%)3 (14.3%)0.735
 *11019 (14.5%)22 (38.6%)0.0865 (12.2%)4 (19%)0.356
 *11054 (6.5%)8 (14%)0.0883 (7.3%)1 (4.8%)0.583
 *11158 (12.9%)3 (5.3%)0.4355 (12.2%)3 (14.3%)0.553
 *11323 (4.8%)3 (5.3%)0.8683 (7.3%)0 (0.0%)0.282
 *11442 (3.2%)6 (10.5)0.3581 (2.4%)1 (4.8%)0.566
 *11661 (1.6%)2 (3.5%)0.5860 (0.0%)1 (4.8%)0.339
*1322 (35.5%)3 (5.3%)0.01619 (46.3%)3 (14.3%)0.014#
 *13017 (11.3%)12 (21.1%)0.2197 (17.1%)0 (0%)0.046#
 *13037 (11.3%)5 (8.8%)0.5255 (12.2%)2 (9.5%)0.558
 *13617 (11.3%)16 (28.1%)0.0797 (17.1%)0 (0%)0.046#
 *13697 (11.3%)3 (5.3%)0.3257 (17.1%)0 (0%)0.046#
*143 (4.8%)0 (0.0%)0.2822 (4.9%)1 (4.8%)1.000
 *14011 (1.6%)0 (0.0%)1.0000 (0.0%)1 (4.8%)0.339
 *14751 (1.6%)0 (0.0%)1.0000 (0.0%)1 (4.8%)0.339
*1511 (17.7%)7 (12.3%)0.72210 (24.4%)1 (4.8%)0.048#
 *15146 (9.7%)3 (5.3%)0.4765 (12.2%)1 (4.8%)0.329
 *15222 (3.2%)9 (15.8%)0.2152 (4.9%)0 (0.0%)0.434

Significant difference at PC ≤ 0.05 between responder and nonresponder patients to treatment. Significant difference at PC ≤ 0.05 (corrected P after the Bonferroni correction) between patients and healthy group. Each patient may have multiple suballeles or none at all, so that totals are not always equal to “ .”

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.